Better aligning diagnostic and drug review processes should be one key focus of upcoming user fee negotiations, says Amy Miller.
Miller is the executive VP of the Personalized Medicine Coalition (PMC), which includes members from the diagnostics and drug industries, as well as the medical, research and financial communities
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Medtech Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?